Effects of an H3R antagonist on the animal model of autism induced by prenatal exposure to valproic acid

PLoS ONE

Volumn 10, Issue 1, 2015, Pages

  Baronio, Diego ^a   Castro, Kamila ^a   Gonchoroski, Taylor ^a   Mueller De Melo, Gabriela ^a   Nunes, Gustavo Della Flora ^a   Bambini Junior, Victorio ^a   Gottfried, Carmem ^a   Riesgo, Rudimar ^a,b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROXIFAN; VALPROIC ACID; ANTIHISTAMINIC AGENT; HISTAMINE H3 RECEPTOR; IMIDAZOLE DERIVATIVE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTISM; COMPULSION; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL SOCIAL BEHAVIOR TEST; FEMALE; MARBLE BURYING TEST; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PAIN THRESHOLD; PRENATAL EXPOSURE; PUP (RODENT); SOCIABILITY; SOCIAL BEHAVIOR; SOCIAL NOVELTY PREFERENCE; TAIL FLICK TEST; ANIMAL; AUTISTIC DISORDER; CHEMICALLY INDUCED; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; METABOLISM; PREGNANCY;

ANIMALIA; MUS;

ANIMALS; AUTISTIC DISORDER; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; FEMALE; HISTAMINE ANTAGONISTS; IMIDAZOLES; MICE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RECEPTORS, HISTAMINE H3; VALPROIC ACID;

EID: 84920458286     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0116363     Document Type: Article

References (46)

1. Happé F, Ronald A (2008) The 'fractionable autism triad': a review of evidence from behavioural, genetic, cognitive and neural research.Neuropsychol Rev 18: 287-304. doi: 10.1007/s11065-008-9076-8 PMID: 18956240
2. Huguet G, Ey E, Bourgeron T (2013) The genetic landscapes of autism spectrum disorders. Annu Rev Genomics Hum Genet 14: 191-213. doi: 10.1146/annurev-genom-091212-153431 PMID: 23875794
3. Christianson AL, Chesler N, Kromberg JG (1994) Fetal valproate syndrome: clinical and neurodevelopmental features in two sibling pairs. Dev Med Child Neurol 36: 361-369. doi: 10.1111/j.1469-8749.1994.tb11858.x PMID: 7512516
4. Bromley RL, Mawer GE, Briggs M, Cheyne C, Clayton-Smith J, et al. (2013) The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. J Neurol Neurosurg Psychiatry 84: 637-643. doi: 10.1136/jnnp-2012-304270 PMID: 23370617
5. Rodier PM, Ingram JL, Tisdale B, Nelson S, Romano J (1996) Embryological origin for autism: developmental anomalies of the cranial nerve motor nuclei. The Journal of comparative neurology 370: 247-261. doi: 10.1002/(SICI)1096-9861(19960624)370:2〈247::AID-CNE8〉3.0.CO;2-2 PMID: 8808733
6. Schneider T, Przewłocki R (2005) Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism. Neuropsychopharmacology 30: 80-89. doi: 10.1038/sj.npp.1300518 PMID: 15238991
7. Bambini-Junior V, Baronio D, MacKenzie J, Zanatta G, dos Santos Riesgo R, et al. (2014) Prenatal Exposure to Valproate in Animals and Autism. Comprehensive Guide to Autism: Springer. pp. 1779-1793.
8. Ferstl R, Akdis CA, O'Mahony L (2012) Histamine regulation of innate and adaptive immunity. Front Biosci (Landmark Ed) 17: 40-53. doi: 10.2741/3914 PMID: 22201731
9. Haas HL, Sergeeva OA, Selbach O (2008) Histamine in the nervous system. Physiol Rev 88: 1183-1241. doi: 10.1152/physrev.00043.2007 PMID: 18626069
10. Naddafi F, Mirshafiey A (2013) The Neglected Role of Histamine in Alzheimer's Disease. Am J Alzheimers Dis Other Demen.
11. Shan L, Bossers K, Luchetti S, Balesar R, Lethbridge N, et al. (2012) Alterations in the histaminergic system in the substantia nigra and striatum of Parkinson's patients: a postmortem study. Neurobiol Aging 33: 1488.e1481-1413. doi: 10.1016/j.neurobiolaging.2011.10.016 PMID: 22118942
12. Tiligada E, Kyriakidis K, Chazot PL, Passani MB (2011) Histamine pharmacology and new CNS drug targets. CNS Neurosci Ther 17: 620-628. doi: 10.1111/j.1755-5949.2010.00212. PMID: 22070192
13. Linday LA (1997) Oral famotidine: a potential treatment for children with autism. Med Hypotheses 48: 381-386. doi: 10.1016/S0306-9877(97)90032-3 PMID: 9185122
14. Carroll LS, Owen MJ (2009) Genetic overlap between autism, schizophrenia and bipolar disorder. Genome Med 1: 102. doi: 10.1186/gm102 PMID: 19886976
15. Konstantareas MM, Hewitt T (2001) Autistic disorder and schizophrenia: diagnostic overlaps. J Autism Dev Disord 31: 19-28. doi: 10.1023/A:1005605528309 PMID: 11439750
16. Kaminsky R, Moriarty TM, Bodine J, Wolf DE, Davidson M (1990) Effect of famotidine on deficit symptoms of schizophrenia. Lancet 335: 1351-1352. doi: 10.1016/0140-6736(90)91237-5 PMID: 1971414
17. Linday LA, Tsiouris JA, Cohen IL, Shindledecker R, DeCresce R (2001) Famotidine treatment of children with autistic spectrum disorders: pilot research using single subject research design. J Neural Transm 108: 593-611. doi: 10.1007/s007020170059 PMID: 11459079
18. Rossi PG, Posar A, Parmeggiani A, Pipitone E, D'Agata M (1999) Niaprazine in the treatment of autistic disorder. J Child Neurol 14: 547-550. doi: 10.1177/088307389901400814 PMID: 10456769
19. Passani MB, Blandina P (2011) Histamine receptors in the CNS as targets for therapeutic intervention. Trends Pharmacol Sci 32: 242-249. doi: 10.1016/j.tips.2011.01.003 PMID: 21324537
20. Schwartz JC (2011) The histamine H3 receptor: from discovery to clinical trials with pitolisant. Br J Pharmacol 163: 713-721. doi: 10.1111/j.1476-5381.2011.01286.x PMID: 21615387
21. Ellenbroek BA, Ghiabi B (2014) The other side of the histamine H3 receptor. Trends Neurosci 37: 191-199. doi: 10.1016/j.tins.2014.02.007 PMID: 24636456
22. Brown JW, Whitehead CA, Basso AM, Rueter LE, Zhang M (2013) Preclinical evaluation of nonimidazole histamine H(3) receptor antagonists in comparison to atypical antipsychotics for the treatment of cognitive deficits associated with schizophrenia. Int J Neuropsychopharmacol 16: 889-904. doi: 10.1017/S1461145712000739 PMID: 22906530
23. Steele SD, Minshew NJ, Luna B, Sweeney JA (2007) Spatial working memory deficits in autism. J Autism Dev Disord 37: 605-612. doi: 10.1007/s10803-006-0202-2 PMID: 16909311
24. Griebel G, Pichat P, Pruniaux MP, Beeské S, Lopez-Grancha M, et al. (2012) SAR110894, a potent histamine H3-receptor antagonist, displays procognitive effects in rodents. Pharmacol Biochem Behav 102: 203-214. doi: 10.1016/j.pbb.2012.04.004 PMID: 22542742
25. Nuutinen S, Vanhanen J, Pigni MC, Panula P (2011) Effects of histamine H3 receptor ligands on the rewarding, stimulant and motor-impairing effects of ethanol in DBA/2J mice. Neuropharmacology 60: 1193-1199. doi: 10.1016/j.neuropharm.2010.10.027 PMID: 21044640
26. Fox GB, Esbenshade TA, Pan JB, Radek RJ, Krueger KM, et al. (2005) Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist. J Pharmacol Exp Ther 313: 176-190. doi: 10.1124/jpet.104.078402 PMID: 15608077
27. Noland JS, Steven Reznick J, Stone WL, Walden T, Sheridan EH (2010) Better working memory for non-social targets in infant siblings of children with Autism Spectrum Disorder. Dev Sci 13: 244-251. doi: 10.1111/j.1467-7687.2009.00882.x PMID: 20121880
28. Brioni JD, Esbenshade TA, Garrison TR, Bitner SR, Cowart MD (2011) Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease. J Pharmacol Exp Ther 336: 38-46. doi: 10.1124/jpet.110.166876 PMID: 20864505
29. Trofimiuk E, Braszko JJ (2014) Single dose of H3 receptor antagonist - ciproxifan - abolishes negative effects of chronic stress on cognitive processes in rats. Psychopharmacology (Berl) 231: 209-219. doi: 10.1007/s00213-013-3227-1 PMID: 23975035
30. da Silveira CK, Furini CR, Benetti F, Monteiro SaC, Izquierdo I (2013) The role of histamine receptors in the consolidation of object recognition memory. Neurobiol Learn Mem 103: 64-71. doi: 10.1016/j.nlm.2013.04.001 PMID: 23583502
31. Roullet FI, Wollaston L, Decatanzaro D, Foster JA (2010) Behavioral and molecular changes in the mouse in response to prenatal exposure to the anti-epileptic drug valproic acid. Neuroscience 170: 514-522. doi: 10.1016/j.neuroscience.2010.06.069 PMID: 20603192
32. Glick SD, Crane LA (1978) Opiate-like and abstinence-like effects of intracerebral histamine administration in rats. Nature 273: 547-549. doi: 10.1038/273547a0 PMID: 566384
33. Huang L, Adachi N, Nagaro T, Liu K, Arai T (2007) Histaminergic involvement in neuropathic pain produced by partial ligation of the sciatic nerve in rats. Reg Anesth Pain Med 32: 124-129. doi: 10.1016/j.rapm.2006.11.009 PMID: 17350523
34. Owen SM, Sturman G, Freeman P (1994) Modulation of morphine-induced antinociception in mice by histamine H3-receptor ligands. Agents Actions 41 Spec No: C62-63. doi: 10.1007/BF02007768 PMID: 7976807
35. Suzuki T, Takamori K, Takahashi Y, Narita M, Misawa M, et al. (1994) The differential effects of histamine receptor antagonists on morphine- and U-50,488H-induced antinociception in the mouse. Life Sci 54: 203-211. doi: 10.1016/0024-3205(94)00589-3 PMID: 7904710
36. Malmberg-Aiello P, Lamberti C, Ghelardini C, Giotti A, Bartolini A (1994) Role of histamine in rodent antinociception. Br J Pharmacol 111: 1269-1279. doi: 10.1111/j.1476-5381.1994.tb14883.x PMID: 8032614
37. Farzin D, Asghari L, Nowrouzi M (2002) Rodent antinociception following acute treatment with different histamine receptor agonists and antagonists. Pharmacol Biochem Behav 72: 751-760. doi: 10.1016/S0091-3057(02)00748-7 PMID: 12175473
38. 3 inverse agonist pitolisant increases thermal pain thresholds. Inflamm Res 61: 1283-1291. doi: 10.1007/s00011-012-0528-5 PMID: 22820944
39. Joshi VV, Balsara JJ, Jadhav JH, Chandorkar AG (1981) Effect of L-histidine and chlorcyclizine on apomorphine-induced climbing behaviour and methamphetamine stereotypy in mice. Eur J Pharmacol 69: 499-502. doi: 10.1016/0014-2999(81)90456-8 PMID: 6113966
40. Ito C, Onodera K, Watanabe T, Sato M (1997) Effects of histamine agents on methamphetamine-induced stereotyped behavior and behavioral sensitization in rats. Psychopharmacology (Berl) 130: 362-367. doi: 10.1007/s002130050251 PMID: 9160852
41. Paschou P (2013) The genetic basis of Gilles de la Tourette Syndrome. Neurosci Biobehav Rev 37: 1026-1039. doi: 10.1016/j.neubiorev.2013.01.016 PMID: 23333760
42. Motawaj M, Arrang JM (2011) Ciproxifan, a histamine H3-receptor antagonist/inverse agonist, modulates methamphetamine-induced sensitization in mice. Eur J Neurosci 33: 1197-1204. doi: 10.1111/j.1460-9568.2011.07618.x PMID: 21366724
43. Saunders JA, Tatard-Leitman VM, Suh J, Billingslea EN, Roberts TP, et al. (2013) Knockout of NMDA receptors in parvalbumin interneurons recreates autism-like phenotypes. Autism Res 6: 69-77. doi: 10.1002/aur.1264 PMID: 23441094
44. Burban A, Sadakhom C, Dumoulin D, Rose C, Le Pen G, et al. (2010) Modulation of prepulse inhibition and stereotypies in rodents: no evidence for antipsychotic-like properties of histamine H3-receptor inverse agonists. Psychopharmacology (Berl) 210: 591-604. doi: 10.1007/s00213-010-1863-2 PMID: 20437030
45. Bristot Silvestrin R, Bambini-Junior V, Galland F, Daniele Bobermim L, Quincozes-Santos A, et al. (2013) Animal model of autism induced by prenatal exposure to valproate: altered glutamate metabolism in the hippocampus. Brain Res 1495: 52-60. doi: 10.1016/j.brainres.2012.11.048 PMID: 23219577
46. Martin HG, Manzoni OJ (2014) Late onset deficits in synaptic plasticity in the valproic acid rat model of autism. Front Cell Neurosci 8: 23. doi: 10.3389/fncel.2014.00023 PMID: 24550781